

# Perspective and Outlook, Summary,

**Samenvatting**

This chapter includes parts of the following publication:

**A perspective towards mass-spectrometry-based *de novo* sequencing of endogenous antibodies**

Sebastiaan C. de Graaf\*, Max Hoek\*, Sem Tamara and Albert J.R. Heck

***mAbs*** (2021), 14:1, 2079449, DOI: 10.1080/19420862.2022.2079449 *Review*

\* These authors contributed equally to this work

# Summary

**ANTIBODIES** are essential to adaptive immunity and represent one of the most polymorphic proteins found in the human body. This polymorphism provides

the incredible flexibility seen in adaptive immunity and makes antibodies a true "per­ sonalized proteome", unique to each individual and adapted to their needs. However, this diversity also makes studying antibodies difficult. The chapters in this thesis de­ tail efforts to develop generalizable data analysis strategies for studying secreted antibody repertoires using mass spectrometry.

**Chapter 2** is on a distinctive topic, as we highlight the importance of having gen­ eralized computational tools to effectively analyze large and complex cross-linking proteomic datasets. While crosslinking MS has emerged as an attractive method to probe protein interactions, the complexity of dealing with protein interactions rather than individual proteins has resulted in the production of large amounts of data, mak­ ing processing difficult, especially for experiments targeting the whole proteome. To address this issue, we developed a tool that is interactive and facilitates analysis and visualization of these large datasets. The tool directly handles the output of XlinkX for Proteome Discoverer but can also be used with output from other plat­ forms through a user-controllable text-file importer. It comes equipped with a spec­ trum viewer and supports preprocessing of replicate datasets, enabling easy han- dling of large amounts of data. We have also integrated data from protein databases Eggnog and Uniprot, which enable integrated gene ontology enrichment analysis, grouping based on function, and mapping of known post-translational modification sites, domains, and secondary structures. Another feature is length-based validation of detected crosslinks by mapping the crosslinked peptides onto validated structural models of proteins or protein complexes. In situations where no structure is available, structures obtained by homology modelling can be used. In such cases, crosslinked peptides are aligned to the homologous sequence to obtain a confident placement

6

of the linked residues before the distance between these residues is calculated us­ ing the 30 structure. Crosslinks between two proteins with known structures where no structure of the complex is available can also be directly submitted to DisVis for visualization and quantification of the information content of distance restraints.

In **Chapter 3,** we show how advancements in intact protein mass spectrometry allow for the detection of lgG1 molecules in human serum with clonal resolution. This en­ abled the construction of personalized lgG1 repertoires. Despite there being an enor­ mous number of theoretically possible clones, the observed antibody repertoires were relatively simple, with only several hundred clones dominating at any given time point. Moreover, while the majority of the clones in these profiles were stable over time, we observed substantial changes in the repertoires following a sepsis episode. We also demonstrated that a combination of peptide- and protein-centric mass spectrometry could be employed to *de nova* sequence individual clones directly from the serum. The peptide-centric approach provided extensive coverage, while the protein-centric (fragmentation) approach provided sequence information that is inherently grouped per clone. The synergy between these techniques was used to sequence a single highly abundant clone from the sample of one of our donors.

**Chapter 4** showcases the potential of antibody repertoire profiling data to compare and characterize individual donors within a group. We constructed SlgA1 profiles for a cohort of six lactating women who had received two identical SARS-CoV-2 vaccina- tions. The resulting profiles complement findings from earlier ELISA-based titer level analysis of these samples, where a biphasic rise in spike-specific lgA was found. Our observations indicate the emergence of a heterogeneous polyclonal population of be- tween 100 and 200 novel clones in all donors after vaccination. This vaccine-induced population is dominated by a persistent population of clones that appear shortly after the initial vaccination and persist until at least five days after the second. However, we also detect a population of clones that emerge more than three days after the

**6**

second vaccination was administered, in every donor. In-depth analysis of a strong responder, selected by ELISA and confirmed by our data, reveals that the second rise in spike-specific lgA coincides with an abundant second dose-induced popula­ tion, highlighting the divergent clonal makeup of what initially seemed like a symmet­ rical biphasic response. Additionally, we observed several highly abundant clones appear and subsequently disappear from the secreted repertoire over the course of

~40 days, showing that highly abundant clones do not necessarily persist over time.

In **Chapter 5,** we built further upon the proof of concept for *de nova* sequencing of endogenous antibodies by mass spectrometry initially presented in Chapter 3 to create a more standardized and broadly applicable workflow for sequencing anti­ body chains in mixtures using a combination of peptide- and protein-centric mass spectrometry. The proposed approach sequences a target chain in a modular, three­ stage process based on germline domains. It starts with sequencing the framework regions, followed by complementarity determining regions with flanking framework regions, and ultimately full chain sequences. Through integration of middle-down fragmentation, we could resolve ambiguity in *de nova* sequence predictions for the hypervariable complementarity determining regions. To achieve this, we filtered can­ didate sequences by comparing their theoretical mass to the gap between adjacent framework regions. We demonstrated the effectiveness of this approach by accu­ rately sequencing a single targeted chain in a pure monoclonal antibody sample, an equimolar mixture of three monoclonal antibodies, and a polyclonal serum sample. This approach provides a broadly applicable workflow that could be used in future studies to sequence complex samples with high accuracy, as well as a step towards full automation of the process.

6

# Perspective and Outlook

Recent work by Wolf et al.(1) demonstrated that an individual's antibody titers are a poor marker of the frequency of memory B cells generated following SARS-CoV-2, seasonal influenza, or EBV infection. If assessing humoral immunity through poly­ clonal antibody titers does not reflect an individual's ability to mount an antibody re­ sponse, we need to find additional ways to determine an individual's level of protec­ tion. The research presented in this thesis describes a promising new strategy to achieve this goal through antibody repertoire characterization by using mass spec­ trometry. By monitoring antibody dynamics at an unprecedented resolution, we can gain new insights into humoral immune responses by uncovering when, how, and why specific antibodies are generated in response to physiological events. Coupled with targeted sequencing of endogenous antibodies by MS, this approach holds ex­ citing potential for drug discovery as integration of these techniques into therapeutic development pipelines could lead to significant advancements in the field. More­ over, large scale profiling of endogenous secreted antibody repertoires may lead to the definition of immune signatures for use in disease risk assessment, diagnostic classification, or measuring treatment effectiveness.


## The importance of standardized tools

**6**

The advancements made over the last decade in MS-based antibody sequencing provide an optimistic outlook for the future. I expect that a therapeutic antibody dis- covered by MS could be right around the corner. Looking back at the timeline of key developments in the field of antibody sequencing, we can notice several clear trends **(Figure 1**). Since the 1960s, rudimentary sample preparation for antibodies was available, but practical methods of obtaining sequence information appeared only in 1993, when Sanger sequencing was first applied to B cells. The first therapeutic an- tibody was registered in 1986, and this advent launched large-scale development of

mAbs, with a hundred mAbs registered by 2008 (2). At that point, next-generation sequencing led to high-throughput sequencing workflows and further facilitated the lead-finding and development of therapeutic antibodies. Over the last 20 years, the rapid expansion of genome-based sequencing techniques kick-started antibody dis­ covery by allowing large-scale BCR sequencing, and the number of deposited anti­ body sequences and registered antibody therapeutics has been growing exponen­ tially ever since, with the 100th therapeutic mAb being approved by the United States Food and Drug Administration (FDA) in 2021 (3). Observing this trend, the popular­ ization of MS-based proteomics has now spurred the development of platforms for *de nova* sequencing of antibodies heavily supported by MS, and I envision that the ongoing advancement of MS based antibody profiling and *de nova* sequencing will complement available strategies by protein-level analysis. More specifically, mon­ itoring of antibody repertoires could be used to select a limited number of reactive antibodies from a patient with an effective immune response, which could then be sequenced, recombinantly produced and screened for neutralizing capacity. Such a direct approach to antibody discovery would be much more straightforward than screening of B-cells at the DNA/RNA level. The impact of accessible, standardized, high throughput analytical methods, can be observed in the discovery of genomic and proteomic biomarkers as well(4, 5). As standardized, high-throughput genomic and proteomic techniques became widely accessible, the number of genomic and proteomic biomarkers for disease risk assessment, early diagnosis, diagnostic clas­ sification and measuring treatment effectiveness rose drastically. I believe the current advances in immune response characterization could represent a similar opportunity, as large-scale, in-depth characterization of proteomic antibody repertoires may lead to the discovery of defined immune signatures that could be used as immunological biomarkers in very similar ways.

**6**



**Figure 1: Timeline of key developments paving the way towards MS-based *de novo* sequencing of serum antibodies.** Blue: Key developments in the field of genomic sequencing. Green: Key advances in the field of antibody research. Orange: Selected hallmark papers in the field of MS-based antibody sequencing. To visualize the impact of therapeutic antibody development, the bar graph indicates the cumulative number of registered antibody-based drugs, and the line shows the number of registrations for a given year.(2)

## Challenges

**Larger sample size needed**

However, several challenges must be overcome before we can realize these goals. At the present time, there is, at the protein level, simply not enough antibody repertoire data to draw generalizable conclusions about antibody repertoire dynamics. While we clearly observe drastic changes in the clonal abundance profiles in response to disease and vaccination, the significance of these clones in relation to the antigen is not yet immediately apparent. The fact that these repertoires are unique to each donor means we cannot simply compare the clonal repertoires of donors to screen for antibodies of interest, which, combined with the complex and heterogenous nature of these responses, makes finding patterns extremely challenging. Larger cohorts will need to be studied, and the obtained longitudinal antibody repertoires should be cor- related to established techniques. Existing techniques like ELISA, BCR sequencing

**6**

and neutralization assays will be well complemented by the detailed characterization of the antibody repertoire. B cell receptor sequencing data could be used to deter­ mine the genetic and cellular origin of circulating clones, shedding light on whether novel clones are the result of somatic hypermutation or if they are the result of a completely new recombination of variable, diversity and joining (VDJ) gene recombi­ nation. Neutralization and binding assays could be used to determine exactly when an effective response emerges which can then be related to changes in the clonal profile. Such information on (individual) Fabs and the B-cells which produce them could be useful in studying the personalized nature of immune responses. As we increasingly correlate other assays to LC-MS Fab profiling data, we may also be able to distill a set of features common to effective neutralizing antibodies.

**Dealing with other subclasses of antibodies**

A complete characterization of the antibody repertoire also requires including more antibody classes and subclasses, such as lgG1-4, lgA1-2, lgM, lgD, and lgE, as they each exhibit a specific tissue distribution and effectiveness against certain pathogens. Upon encountering antigens, B cells produce specific immunoglobulin classes and subclasses, depending on the antigen type and entry mode. In humans, lgG1 and lgG3 are effective against viruses, lgG2 against encapsulated bacteria, lgG4 and lgE against large extracellular parasites, and lgA1 and lgA2 against pathogenic bacte- ria at mucosal sites (6, 7). As these subclasses target different antigens, it follows that their fab repertoires would not completely overlap. However, while differences between antibody classes and subclasses have been described extensively, compar­ atively little is known about their Fab repertoires. By comparing these repertoires we may gain a better understanding of the interplay between them. The current Fab pro­ filing methodologies for antibody characterization by mass spectrometry are focused on the two most abundant isotypes in humans, lgG1 and lgA1, as they require highly specific Fab-cleaving proteases that are only available for these isotypes. However,

6

with the increasing demand for proteomic antibody characterization, it is likely that additional proteases will be developed, enabling the study of Fab repertoires of less abundant immunoglobulin subclasses and leading to a more complete understanding of the humoral immune response.

**Dealing with low-abundant clones**

A deep characterization of the proteomic antibody repertoire would also be highly de­ sirable, as long lived, protective clones may not be among the most abundant fraction of the repertoire. While the observed proteomic repertoires were simple, consisting of 50-500 clones and dominated by a few abundant clones, the dynamic range of these secreted antibodies was wide and there may still be low abundant clones at concentrations below the current limit of detection. This is compounded by the fact that obtaining accurate uncharged, deisotoped masses for intact proteins (i.e. de­ convolution) is an incredibly challenging task, particularly for low abundant species in complex samples. As we identify clones by mass and retention time, inconsistent mass determination impedes our ability to perform longitudinal tracking of clones in question and can lead to an underestimation of clonal longevity and an inability to deconvolute the LC-MS signal of a clone to an "antibody-like" Fab mass (i.e., a mass of 45-53 kDa) will result in failure to identify said clone. Similarly, a robust chromatog­ raphy setup is required to prevent shifts in retention time due to an unstable system.

**6**

**Clonal lineage analysis and profiling MS**

Outside of experimental variation or artefacts of spectral processing, antibodies are highly polymorphic species and as such are subject to constant mutations which al­ most certainly lead to significant mass- and retention time shifts. Mutated clones would therefore show up as novel species in the antibody repertoire. While the ability to distinguish between these clones makes our analysis powerful, it also means that

we are unable to identify clones with a shared clonal ancestor. While such clonal lineage analysis should in theory be greatly facilitated by referring detected masses to BCR-sequencing data, we have only observed a very small overlap between these two data streams. This apparent disjoint between the genomic or transcriptomic BCR sequences and proteomic data suggests that we are still missing a piece of the puz­ zle. A possible explanation lies in the sampling of the sequenced B cells. The most commonly used B cells for BCR sequencing are peripheral B cells, which only repre­ sent about 2% of the total B cell population (8).

**The need for sequencing/disjoint BCR**

While limited sequence information, in the form of sequence tags for example (9), can be used to reject the possibility of a shared clonal lineage, complete certainty requires full knowledge of the protein sequence of two clones. Unfortunately, in the current stage of implementation, *de nova* sequencing of antibodies is not suitable for such analysis or at least not at a significant scale, as it is still a highly challeng­ ing task which requires manual curation by experts to derive the correct sequence. This manual curation is not only time-consuming, but also makes the process subject to interpretation errors when compared to more established sequencing techniques such as next generation DNA/RNA sequencing. As such, the need for automation is high, to improve not only the throughput but also the reproducibility and robustness.

6

**Sequencing-specific challenges**

Several challenges need to be overcome to achieve automated sequencing of abun­ dant clones in polyclonal mixtures. Similar to deconvolution of intact mass spectra (MS1), accurate and consistent deconvolution of fragmentation spectra (MS2) is im­ mensely challenging, doubly so as signal intensity is split across multiple fragments. Low abundant fragments are difficulty to acquire, and fragment coverage (i.e. the

fraction of amide bonds that have one or more matching fragment mass in the spec­ trum) is typically limited (10). Peptide-centric analysis are hindered by the presence of other clones with homologous sequences, short peptide length and low depth of coverage, which make read assembly exceptionally challenging. Nevertheless, leveraging the synergy between the peptide- and protein-centric MS, as well as the available germline sequences has made sequencing of abundant clones in serum possible, and the generalizable workflow presented in this thesis can be used as a steppingstone towards full automation.

**Factors impacting sequencing strategies**

As antibody samples can be incredibly diverse, a big challenge for a robust antibody sequencing workflow is keeping the workflow broadly applicable. The optimal strat­ egy for a sequencing experiment depends on many factors: How many other clones are in the sample? Are these other clones relatively abundant compared to your target clone? Are specific proteases available to facilitate middle down analysis? How much sample is available? Are there coeluting clones? Is there the possibil­ ity for affinity purification or fractionation prior to sequencing? How divergent is the clone from the germline sequence? How good is bottom-up coverage? How good is top-down coverage? Many of these questions cannot be answered before starting

**6**

the experiment or require additional experiments and therefore time, resources, and sample. While this may seem like a negative outlook, it is good to remember that just a few years ago detection and deconvolution of individual antibody clones in com- plex samples such as serum seemed practically impossible and sequencing even more so. The incredible advances in the field of biomolecular mass spectrometry over the past decades are an indication that there really is no telling how far we can still improve through incremental improvements, not only to spectral processing and acquisition but also to downstream processing of the data. In my opinion, the cur- rent stage of implementation of *de nova* sequencing of endogenous antibodies has

only scratched the surface of the possibilities, and there is a litany of opportunities to improve data analysis, instrumentation and protocol adaptations that are readily available.

**Protein centric improvements**

Nano-flow LC-MS can reduce sample requirements up to 100x, making it possible to acquire more middle down fragmentation data using the same sample. However, these systems are less robust than the high-flow systems used in our current ex­ perimental protocol (11, 12). Parallel acquisition strategies as seen in several 2D­ MS techniques could be used to boost signal intensity (13-15), and super resolution methods could provide greater resolving power (16). Improving precursor selection for fragmentation either by implementing some form of real-time processing (17) or providing an inclusion list of target precursors based on a separate full MS spec­ trum of the same sample. Additionally, while the current generalized implementation uses fragmented reduced antibody chains, fragmentation of intact fabs through ECO can yield highly complementary fragments which could be beneficial to the sequenc­ ing process (18). Furthermore, additional fragmentation methods could be used to increase sequence coverage, as different fragmentation methods will preferentially fragment different backbone positions (19, 20). We have also landed on the Xtract and Respect deconvolution algorithms as our deconvolution method of choice, but there are alternatives out there. One drawback of our current methodology is that it is restricted to deconvolution of scans from a single raw file and does not allow for manual selection of MS2 scans to average for deconvolution, instead only supporting averaging scans over a selected retention time window. Ms\_deisotope (21) is one such alternative that could be explored.

**6**

**Peptide centric improvements**

Our peptide centric efforts have been centered around using the *de nova* read as­ sembly tool stitch (22), combined with PEAKS *de nova* sequencing suite (23), both of which are under continued development along, as are *de nova* peptide sequenc­ ing algorithms and are thus likely to show improved performance over time. While the employed peptide-centric experimental strategies are highly optimized through selection of complementary proteases and defining a robust data acquisition method (24), we still find ways to improve throughput or performance regularly, for example through the use of SP3 beads (25), and potential future improvements could include providing exclusion lists of known constant region peptides.

## Conclusion

The work presented in this thesis emphasizes the need for advanced analytical strate­ gies in studying antibody dynamics and showcases the potential of MS-based pro­ teomics as one such strategy. In doing so, I hope to have made studying these com­ plex molecules less daunting for future researchers by outlining analytical strategies for untangling them. Historically, the complexity of antibodies has made them difficult to analyze on a large scale, as they lack the universal protein sequence databases

6

used in other proteomic studies. However, recent advances in MS-based proteomics and *de nova* sequencing have paved the way for their inclusion, as evidenced by the increasing number of published strategies for proteomic analysis of these repertoires. Combined with the immunological studies of unparalleled scale that we are seeing since the SARS-CoV-2 pandemic, the stage now looks to be set for large scale, in depth, proteomic analysis of endogenous antibody repertoires. The incredible ad- vances in studying these repertoires in multidisciplinary, collaborative studies has left me feeling highly optimistic about the future of this field. Through comprehensive analysis of endogenous antibody repertoires we can gain a deeper understanding of

the immune responses they are a part of and I believe that mass spectrometry will play an integral role in untangling these personalized proteomes.

6

# Samenvatting

Antilichamen zijn een essentieel onderdeel van ans immuun systeem en behoren tot de meest polymorfe eiwitten in het menselijk lichaam. Dit polymorfisme zorgt voor de ongelooflijke flexibiliteit van het verworven immuunsysteem en maakt ans antili­ chamen repertoire tot een "gepersonaliseerd proteoom", uniek voor elk individu en aangepast aan diens behoeften. Deze diversiteit maakt het analyseren van antili­ chamen echter oak zeer uitdagend. De hoofdstukken in dit proefschrift beschrijven mijn contributies aan het ontwikkelen van generaliseerbare computationale analyse strategieen voor het bestuderen van antilichaam repertoires met behulp van massa­ spectrametrie.

**Hoofdstuk 2** is uniek in dit praefschrift, omdat we het belang benadrukken van al­ gemene computationele hulpmiddelen om grate en complexe crasslinking protea­ mies datasets effectief te analyseren. Crasslinking MS is een aantrekkelijke me­ thode geworden om eiwitinteracties te onderzoeken, maar levert zeer grate datasets op, omdat de complexiteit van eiwitinteracties exponentieel stijgt ten opzichte van individuele eiwitten. Dit heeft geleid tot de praductie van grate hoeveelheden com­ plexe datasets waarvan interpretatie moeilijk is, vooral voor experimenten gericht op het gehele proteoom. Om dit probleem te verhelpen hebben wij een interactief

**6**

pragramma ontwikkeld dat de analyse en visualisatie van deze grate datasets verge- makkelijkt. Het pragramma, CrosslD, verwerkt de output van XlinkX voor Proteome Discoverer, maar kan oak warden gebruikt met output van andere platforms door een flexibele import-module. Het kan spectra annoteren en visualiseren en onder- steunt de analyse van replicaten, zodat grate hoeveelheden gegevens gemakkelijk kunnen warden verwerkt. We hebben oak gegevens ge'integreerd uit de Eggnog en Uniprot databases, die ge'integreerde genontologieverrijkingsanalyse, graepering op basis van eiwitfunctie, en visualisatie van bekende posttranslationele modificatie- plaatsen, domeinen en secundaire structuren mogelijk maken. Een andere functie

is validatie van gedetecteerde crosslinks middels hun lengte door het plaatsen van de gecrosslinkede peptiden op gevalideerde structurele modellen van eiwitten of ei­ witcomplexen. In situaties waarin geen structuur beschikbaar is, kunnen structuren verkregen door homologiemodellering worden gebruikt. In dergelijke gevallen war­ den gecrosslinkede peptiden met behulp van sequentiealignering (Engels: sequence alignment) geplaatst op de homologe sequentie om een betrouwbare plaatsing van de gekoppelde residuen te verkrijgen waarna de afstand tussen deze residuen wordt berekend aan de hand van de 3D-structuur. Crosslinks tussen twee eiwitten met be­ kende structuren waar geen structuur van het complex beschikbaar is kunnen ook direct worden ingediend bij DisVis voor visualisatie en kwantificering van de informa­ tie in de crosslinks. Hierbij worden de crosslinks, en het feit dat deze een bekende min- en maximum lengte hebben, gebruikt om een structuur te genereren die zo goed mogelijk overeenkomt met de crosslinking data.

In **hoofdstuk 3** laten we zien dat ontwikkelingen in eiwitmassaspectrometrie de de­ tectie van individuele lgG1-moleculen in menselijk serum mogelijk maakt, met klonale resolutie. Dit stelde ons in staat om gepersonaliseerde klonale lgG1-repertoires te construeren. Deze serologische repertoires werden gedomineerd door enkele hon­ derden klonen, een onverwachts laag aantal wanneer het enorme aantal theoretisch mogelijke klonen in acht wordt genomen. Bovendien waren deze profielen groten- deels stabiel: Het merendeel van de gedetecteerde klonen was langdurig aanwezig. We zagen echter ook aanzienlijke veranderingen in de repertoires na een sepsis­ episode. Tevens hebben we aangetoond dat een combinatie van peptide- en eiwit­ gerichte massaspectrometrie kan worden gebruikt om de sequentie van individuele klonen uit het serum *de nova* te bepalen. De peptide-centrische benadering levert hierbij een uitgebreide dekking op, terwijl de eiwit-centrische benadering sequentie­ informatie oplevert die per definitie gegroepeerd is per kloon. De synergie tussen deze technieken werd gebruikt om de sequentie van een enkele zeer abundante

**6**

kloon uit het serum van een van onze donoren te bepalen.

**Hoofdstuk 4** beschrijft hoe wij de antilichaam repertoire-profileringstechniek uit Hoofd­ stuk 3 gebruikt hebben om individuele donoren binnen een groep te vergelijken en te karakteriseren. We hebben SlgA1-profielen samengesteld voor moedermelk van een cohort van zes moeders, die twee identieke SARS-CoV-2 vaccinaties hadden ontvangen. De betreffende profielen vormden een aanvulling op bevindingen van eerdere ELISA-gebaseerde analyse van deze monsters, waarbij een bifasische stij­ ging van spike-specifiek lgA werd gevonden. In alle donoren detecteerden wij een heterogene polyklonale populatie van tussen de 100 en 200 klonen die na vaccinatie onstonden. Deze populatie werd gedomineerd door populatie van persistente klonen die kort na de eerste vaccinatie verschijnt en blijft bestaan tot ten minste vijf dagen na de tweede vaccinatie. Wij observeerden bij elke donor ook een populatie klonen die pas meer dan drie dagen na de tweede vaccinatie ontstaan. Diepgaande analyse van een sterke responder, geselecteerd door ELISA en bevestigd door onze analyse, toonde aan dat de tweede stijging van spike-specifiek lgA van deze donor werd ge­ dreven door een zeer abundante populatie van door de tweede dosis ge"induceerde klonen, wat de uiteenlopende klonale samenstelling benadrukt van wat aanvanke­ lijk leek op een symmetrische bifasische respons. Bovendien zagen we enkele zeer abundante klonen verschijnen en vervolgens verdwijnen uit het repertoire in een pe­ riode van ~40 dagen, waaruit blijkt dat zeer overvloedige klonen niet noodzakelijk langdurig dominant blijven.

6

In **hoofdstuk 5** bouwen we op in hoofdstuk 3 gelegde funderingen voor antilichaam­ sequentiebepaling, door een meer gestandaardiseerde en algemeen toepasbare com­ putationele workflow te creeren voor de *de nova* sequentiebepaling van antilichaam­ ketens in mengsels met behulp van een combinatie van peptide- en eiwitgerichte massaspectrometrie. Onze aanpak bepaalt de sequentie van een geselecteerde ei­ witketen in een modulair, drieledig proces op basis van sequentiedomeinen. We

beginnen met het bepalen van de sequentie van de geconserveerde domeinen, de zogeheten "framework" regios. Vervolgens bepalen we de sequentie van de com­ plementariteitsbepalende regios en de aangrenzende framework regios, voordat we uiteindelijk de sequentie van de volledige eiwitketen bepalen. Door het gebruik van middle-down fragmentatie konden we de ambigu"fteit in de hypervariabele comple­ mentariteitsbepalende regios oplossen. Daartoe filterden wij kandidaat-sequenties door hun theoretische massa te vergelijken met het "gat" tussen de aangrenzende framework regios. We hebben de effectiviteit van deze aanpak aangetoond door de sequentie van een antilichaamketen te bepalen in drie monsters: Een zuiver mo­ noklonaal antilichaammonster, een equimolair mengsel van drie monoklonale antili­ chamen en een polyklonaal serummonster. Deze aanpak biedt een generaliseerbare workflow die in toekomstige studies kan worden gebruikt om complexe monsters met hoge nauwkeurigheid te sequencen en brengt ons dichter bij volledige automatise­ ring van dit proces.

6

# References

1. Carla Wolf, Sebastian Koppert, Noemi Becza, et al. Antibody levels poorly reflect on the frequency of memory b cells gen­ erated following sars-cov-2, seasonal influenza, or ebv infec­ tion. *Cells,* 11(22), 2022. ISSN 2073-4409. doi: 10.3390/

cells11223662.

1. Matthew I J Raybould, Claire Marks, Alan P Lewis, et al. Thera­ sabdab: the therapeutic structural antibody database. *Nucleic acids research,* 48(1):383-388, 2020. ISSN 1362-4962. doi: 10.1093/nar/gkz827.
2. Asher Mullard. Fda approves 100th monoclonal antibody prod­ uct. *Nature reviews. Drug discovery,* 20(7):491-495, 2021. ISSN 1474-1784. doi: 10.1038ld41573-021-00079-7.
3. Richard Simon. Genomic biomarkers in predictive medicine. an interim analysis. *EMBO Molecular Medicine,* 3(8):429, 2011. ISSN 17574676. doi: 10.1002/emmm.201100153.
4. Miao Cui, Chao Cheng, and Lanjing Zhang. High-throughput proteomics: a methodological mini-review. *Laboratory inves­ tigation;* a *journal of technical methods and pathology,* 102 (11):1170-1181, 2022. ISSN 1530-0307. doi: 10.1038/ s41374-022-00830-7.
5. Gestur Vidarsson, Gillian Dekkers, and Theo Rispens. lgg subclasses and allotypes: From structure to effector functions. *Frontiers in Immunology,* 5, 2014. ISSN 16643224. doi: 10.3389/fimmu.2014.00520.
6. Zhenming Xu, Hong Zan, Egest J. Pone, Thach Mai, and Paolo Casali. lmmunoglobulin class switch dna recombination: induc­ tion, targeting and beyond. *Nature reviews. Immunology,* 12(7): 517, 2012. ISSN 14741733. doi: 10.1038/rni3216.
7. Adrian Guthals, Yutian Gan, Laura Murray, et al. De nova ms/ms sequencing of native human antibodies. *Journal of Pro­ teome Research,* 16(1):45-54, 2017. ISSN 1535-3893. doi: 10.1021/acs.jproteome.6b00608.
8. David L. Tabb, Ma Ze-Qiang, Daniel 8. Martin, Amy Joan L. Ham, and Matthew C. Chambers. Directag: Accurate se­ quence tags from peptide ms/ms through statistical scoring. *Journal of Proteome Research,* 7(9):3838-3846, 2008. ISSN 15353893. doi: 10.1021/pr800154p.
9. Lidong He, Chad R. Weisbrod, and Alan G. Marshall. Protein de nova sequencing by top-down and middle-down ms/ms: Limi­ tations imposed by mass measurement accuracy and gaps in sequence coverage. *International Journal of Mass Spectrom­ etry,* 427:107-113, 2018. ISSN 13873806. doi: 10.1016lj.ijms.

2017.11.012.

1. Matthias Wlm and Matthias Mann. Analytical properties of the nanoelectrospray ion source. *Analytical Chemistry,* 68(1):1-8, 1996. ISSN 00032700. doi: 10.1021/ac9509519/assel/images/ large/ac9509519f00006.jpeg.
2. Christine L. Gatlin, Gerd R. Kleemann, Lara G. Hays, Andrew J. Link, and John R. Yates. Protein identification at the low femto­ mole level from silver-stained gels using a new fritless elec­ trospray interface for liquid chromatography-microspray and nanospray mass spectrometry. *Analytical Biochemistry,* 263 (1):93-101, 1998. ISSN 0003-2697. doi: 10.1006/abio.1998.

2809.

1. Catherine G. Vasilopoulou, Karolina Sulek, Andreas-David Brunner, et al. Trapped ion mobility spectrometry and pasef enable in-depth lipidomics from minimal sample amounts. *Na­ ture Communications,* 11(1):331, 2020. ISSN 2041-1723. doi: 10.1038/s41467-019-14044-x.
2. Mark E. Ridgeway, Markus Lubeck, Jan Jordens, Mattias Mann, and Melvin A. Park. Trapped ion mobility spectrometry: A short review. *International Journal of Mass Spectrometry,* 425:22-35, 2018. ISSN 1387-3806. doi: 10.1016/j.ijms.2018.

6

01.006.

1. Katherine A Graham, Charles F Lawlor, and Nicholas B Baratto. Characterizing the top-down sequencing of protein ions prior to mobility separation in a timstof. 2023. doi: 10.26434/chemrxiv-2022-w8s4n-v3.
2. Dmitry Grinfeld, Konstantin Aizikov, Arne Kreutzmann, Eugen Damoc, and Alexander Makarov. Phase-constrained spectrum deconvolution for fourier transform mass spectrometry. *Analyt­ ical Chemistry,* 89(2):1202-1211, 2017. ISSN 15206882. doi:

10.1021/acs.analchem.6b03636.

(17] Kyowon Jeong, Masa Babovic, Vladimir Gorshkov, et al. Flashida enables intelligent data acquisition for top-down pro­ teomics to boost proteoform identification counts. *Nature com­ munications,* 13(1), 2022. ISSN 2041-1723. doi: 10.1038/ s41467-022-31922-z.

1. Maurits A. den Boer, Jean-Francois Greisch, Sem Tamara, Al­ bert Bandt, and Albert J. R. Heck. Selectivity over coverage in de novo sequencing of iggs. *Chemical science,* **11**(43):11886- 11896, 2020. ISSN 2041-6520. doi: 10.1039/d0sc03438j.
2. Mathieu Dupre, Magalie Duchateau, Rebecca Sternke-

(22] Douwe Schulte, Weiwei Peng, and Joost Snijder. Template­ based assembly of proteomic short reads for de nova antibody sequencing and repertoire profiling. *Analytical chemistry,* 94 (29):10391-10399, 2022. ISSN 1520-6882. doi: 10.1021/acs.

analchem.2c01300.

[23] Bin Ma, Kaizhong Zhang, Christopher Hendrie, et al. Peaks: powerful software for peptide de nova sequencing by tandem mass spectrometry. *Rapid Communications in Mass Spec­ trometry,* 17(20):2337-2342, 2003. ISSN 0951-4198. doi: 10.1002lrcm.1196.

Hoffmann, et **al.** De nova sequencing of antibody light chain [24] Weiwei Peng, Matti F. Pronker, and Joost Snijder. Mass

proteoforms from patients with multiple myeloma. *Analytical Chemistry,* 93(30):10627-10634, 2021. ISSN 15206882. doi:

10.1021/acs.analchem.1c01955.

1. Jennifer S. Brodbelt. Ion activation methods for peptides and proteins. *Analytical Chemistry,* 88(1):30-51, 2016. ISSN

15206882. doi: 10.1021/acs.analchem.5b04563.

1. Joshua Klein, heckendorfc, SauIius Lukauskas, and mstim. mobiuskleinlmsdeisotope: Release v0.0.33. 2021. doi: 10. 5281/zenodo.5759830.

spectrometry-based de novo sequencing of monoclonal an­ tibodies using multiple proteases and a dual fragmentation scheme. *Journal of Proteome Research,* 20(7):3559-3566, 2021. ISSN 1535-3893. doi: 10.1021/acs.jproteome.1c00169.

[25] Harvey E. Johnston, Kranthikumar Yadav, Joanna **M.** Kirk­ patrick, et al. Solvent precipitation sp3 (sp4) enhances recov­ ery for proteomics sample preparation without magnetic beads. *Analytical Chemistry,* 94(29):10320-10328, 2022. ISSN

15206882. doi: 10.1021/acs.analchem.1c04200lsupplfilel ac1c04200si002.xlsx.